调强放疗联合化疗对晚期非小细胞肺癌血清三种因子表达变化的队列研究

doi:10.3760/cma.j.cn113030-20210103-00003

Abstract
Figure/Table
References(20)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To investigate the changes of the expression levels of serum proliferating cell nuclear antigen (PCNA), tumor-specific growth factor (TSGF), soluble E-cadherin (SE-CAD) and the relationship with clinical prognosis of advanced non-small cell lung cancer (NSCLC) patients treated with intensity-modulated radiotherapy combined with chemotherapy. Methods Eighty-four patients (29 cases of ⅢA, 30 ⅢB and 25 Ⅳ) with advanced NSCLC treated in our hospital from January 2016 to January 2018 were selected, and all patients were given with intensity-modulated radiotherapy combined with chemotherapy. The expression levels of serum PCNA, TSGF, and SE-CAD were compared among different TNM stages and before and after treatment. The serum PCNA, TSGF, SE-CAD levels were compared among patients with different clinical efficacy. The relationship between serum PCNA, TSGF and SE-CAD levels and clinical efficacy was assessed by Logistic regression analysis. The survival analysis was performed with Kaplan-Meier method. Results The expression levels of serum PCNA, TSGF and SE-CAD before treatment in stage Ⅳ patients were significantly higher than those in stage ⅢB and ⅢA patients (584.11±60.25 pg/ml vs. 531.06±51.37 pg/ml and 477.54±46.49 pg/ml, 96.13±7.54 U/ml vs. 8.52±5.91 U/ml and 82.41±5.0 U/ml, 3.02±0.26 ng/ml vs. 2.87±0.22 ng/ml and 2.71±0.15 ng/ml, all P<0.05), and the serum levels of three cytokines in ⅢB stage patients were significantly higher than those in their ⅢA stage counterparts (all P<0.05). After treatment, the serum levels of PCNA, TSGF and SE-CAD were significantly lower than those before treatment (396.11±50.23 pg/ml vs. 528.37±75.09 pg/ml, 74.81±4.72 U/ml vs. 88.68±6.13 U/ml, 1.92±0.24 ng/ml vs.2.86±0.31 ng/ml, all P<0.05). At 18 months after treatment, the serum levels of PCNA, TSGF and SE-CAD in surviving patients were significantly lower than those of dead patients (332.51±54.32 pg/ml vs. 444.92±60.07 pg/ml, 70.59±6.20 U/ml vs. 78.05±8.44 U/ml, 1.71±0.24 ng/ml vs. 2.08±0.27 ng/ml, all P<0.05). The serum levels of PCNA, TSGF and SE-CAD were significantly associated with clinical prognosis (all P<0.05). Among 84 NSCLC patients, the >Objective response rate after treatment was 29%(24/84). The survival curves in patients with high expression levels of serum PCNA, TSGF and SE-CAD were significantly lower than those in the low-expression group (all P<0.05). Conclusion Serum PCNA, TSGF and SE-CAD are highly expressed in patients with advanced NSCLC, which are closely correlated with clinical staging and prognosis and contribute to predicting survival status.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tian Hanhan
	Zhou Xilei
	Chen Wei
	Yu Changhua

Key words： Neoplasm,non-small cell lung/intensity-modulated radiotherapy Neoplasm,non-small cell lung/chemotherapy Proliferating cell nuclear antigen Tumor-specific growth factor Soluble E-cadherin

Received: 03 January 2021

Fund:Huaian City Natural Science Research Program (HAB201928)

Corresponding Authors: Yu Changhua, Email:yuchh11@163.com

Cite this article:

Tian Hanhan,Zhou Xilei,Chen Wei et al. Cohort study of changes in expression of three serum cytokines in patients with advanced non-small cell lung cancer after intensity-modulated radiotherapy combined with chemotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1007-1012.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20210103-00003 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I10/1007

[1] 文慧,彭彦才,艾葆春,等. 容积弧形调强放疗同步化疗治疗晚期非小细胞肺癌患者的短期疗效及对血清TSGF、TK1、CA125水平的影响[J]. 现代生物医学进展,2019, 19(14):2760-2763. DOI:10.13241/j.cnki.pmb.2019.14.034.
Wen H, Peng YC, Ai BC, et al. Short-term clinical efficacy of volume-arc intensity modulated radiotherapy in the treatment of advanced non-small cell lung cancer and its effects on the serum TSGF, TK1 and CA125 levels[J]. Prog Mod Biomed, 2019, 19(14):2760-2763. DOI:10.13241/j.cnki.pmb.2019.14.034.
[2] Li Q, Kim J, Balagurunathan Y, et al. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy[J]. Radiat Oncol, 2017, 12(1):158. DOI:10.1186/s13014-017-0892-y.
[3] 顾万娟,杜希林. IL-6、TSGF联合肿瘤标记物CEA、CA724检测在胃癌中的诊断价值[J]. 检验医学与临床,2019, 16(12):1709-1711. DOI:10.3969/j.issn.1672-9455.2019.12.023.
Gu WJ, Du XL. Diagnostic value of combined detection of serum IL-6, TSGF, CEA and CA724 in gastric cancer[J]. Lab Med Clin, 2019, 16(12):1709-1711. DOI:10.3969/j.issn.1672-9455.2019.12.023.
[4] Sotgia F, Lisanti MP. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients:use as companion diagnostics[J]. Oncotarget, 2017, 8(40):68095-68107. DOI:10.18632/oncotarget.19677.
[5] 武彩虹,银广悦,钱成荣,等. 血清黏附分子SE-CAD、SE-SEL和sICAM-1在肺癌诊断中的应用[J]. 临床输血与检验,2017, 19(4):382-385. DOI:10.3969/j.issn.1671-2587.2017.04.021.
Wu CH, Yin GY, Qian CR, et al. Serum adhesion molecules SE-Cadherin, SE-Selectin and sICAM-1 as lung cancer biomarkers[J]. J Clin Trans Lab Med, 2017, 19(4):382-385. DOI:10.3969/j.issn.1671-2587.2017.04.021.
[6] 杨龙海,叶波,魏星,等. 最新国际肺癌TNM分期标准(第8版)修订稿解读[J]. 中国医刊,2016, 51(9):22-25. DOI:10.3969/j.issn.1008-1070.2016.09.006.
Yang H, Ye B, Wei X, et al. Interpretation of the revised version of the latest international TNM staging standard for lung cancer (8th ed)[J]. Chin J Med, 2016, 51(9):22-25. DOI:10.3969/j.issn.1008-1070.2016.09.006.
[7] Zhang Y, Zhang X, Ye M, et al. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein[J]. Cancer Lett, 2018, 44(419):75-83. DOI:10.1016/j.canlet.2018.01.047.
[8] 邓超,谭建军,蔡祖艾,等. 前程三维适形放疗与后程调强放疗+含紫杉醇方案治疗晚期非小细胞肺癌患者的疗效观察[J]. 疑难病杂志,2019, 18(7):678-681. DOI:10.3969/j.issn.1671-6450.2019.07.008.
Deng C, Tan JJ, Cai ZA, et al. Forward three-dimensional conformal radiotherapy and late-course intensity-modulated radiotherapy plus paclitaxel-containing regimen chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Chin J Diff Compl Cases, 2019, 18(7):678-681. DOI:10.3969/j.issn.1671-6450.2019.07.008.
[9] 张新华,王庆亮,赵坤.miR-214对人舌鳞状细胞癌增殖能力影响的体外实验研究[J]. 中华生物医学工程杂志,2014, 20(4):268-271. DOI:10.3760/cma.j.issn.1674-1927.2014.04.002.
Zhang XH, Wang QL, Zhao K. Effect of miR-214 on proliferation of human tongue cancer cell line in-vitro[J] Chin J Biomed Engin, 2014, 20(4):268-271. DOI:10.3760/cma.j.issn.1674-1927.2014.04.002.
[10] Trasviña-Arenas CH, Cardona-Felix CS, Azuara-Liceaga E, et al. Proliferating cell nuclear antigen restores the enzymatic activity of a DNA ligase I deficient in DNA binding[J]. FEBS Open Biol, 2017, 7(5):659-674. DOI:10.1002/2211-5463.12209.
[11] 郝艳萍,王光. 非小细胞肺癌患者血清PCNA和癌组织NapsinA表达及与病理类型的关系[J]. 标记免疫分析与临床,2017, 24(11):1235-1238. DOI:10.11748/bjmy.issn.1006-1703.2017.11.010.
Hao YP, Wang G. The relationship between the expression and pathological type of serum pcna and carcinoma tissues of non-small cell lung cancer patients[J]. Labe Immun Clin Med, 2017, 24(11):1235-1238. DOI:10.11748/bjmy.issn.1006-1703.2017.11.010.
[12] 赵莲,郑子阳,钟敏. 血清PDCD5和PCNA表达对肺癌患者短期预后的评估价值[J]. 临床和实验医学杂志,2019, 18(11):1149-1152. DOI:10.3969/j.issn.1671-4695.2019.11.008.
Zhao L, Zheng ZY, Zhong M. The evaluated values of serum levels of PDCD5 and PCNA to the short-term prognosis in patients with lung cancer[J]. J Clin Exp Med, 2019, 18(11):1149-1152. DOI:10.3969/j.issn.1671-4695.2019.11.008.
[13] Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer[J]. Int J Mol Sci, 2014, 15(6):9546-9565. DOI:10.3390/ijms15069546.
[14] 郑爽,金毅,王振. 新型肿瘤标志物TSGF和Hsp90α与非小细胞肺癌的临床相关性分析[J]. 医学研究杂志,2019, 48(6):114-117. DOI:10.11969/j.issn.1673-548X.2019.06.026.
Zheng S, Jin Y, Wang Z. New tumor markers TSGF and Hsp90 α clinical correlation analysis with non-small cell lung cancer[J]. J Med Res, 2019, 48(6):114-117. DOI:10.11969/j.issn.1673-548X.2019.06.026.
[15] 薛鸿涛,任敏,李长彬. 非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J]. 现代检验医学杂志,2016, 31(2):136-138. DOI:10.3969/j.issn.1671-7414.2016.02.041.
Xue HT, Ren M, Li CB. Changes and clinical significance of serum TSGF and CRP in patients with non-small cell lung cancer before and after radiotherapy[J]. J Mod Lab Med, 2016, 31(2):136-138. DOI:10.3969/j.issn.1671-7414.2016.02.041.
[16] 李秀荣. TSGF在原发性肝癌TACE治疗中疗效评估的应用价值[J]. 中国医师杂志,2017, 19(2):253-256. DOI:10.3760/cma.j.issn.1008-1372.2017.02.023.
Li XR. Application value of TSGF in TACE treatment of primary liver cancer[J]. Chin J Physi, 2017, 19(2):253-256. DOI:10.3760/cma.j.issn.1008-1372.2017.02.023.
[17] Brusgard JL, Choe M, Chumsri S, et al. RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells[J]. Oncotarget, 2015, 6(29):28132-28150. DOI:10.18632/oncotarget.4654.
[18] 刘昱,武彩虹,田雪梅,等. 血清TK-1、SE-CAD表达及联合HE4、CEA、CYFRA21-1检测在非小细胞肺癌诊断中的意义[J]. 标记免疫分析与临床,2019, 26(6):960-962, 970. DOI:10.11748/bjmy.issn.1006-1703.2019.06.015.
Liu Y, Wu CH, Tian XM, et al. Significance of serum TK-1 and SE-CAd expression and combined detection of HE4, CEA and CYFRA21-1 in the diagnosis of non-small cell lung cancer[J]. Mark Immun Clin, 2019, 26(6):960-962, 970. DOI:10.11748/bjmy.issn.1006-1703.2019.06.015.
[19] Hussein S, Mosaad H, Rashed HE, et al. Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features[J]. Mol Biol Rep, 2017, 44(4):365-377. DOI:10.1007/s11033-017-4118-z.
[20] 苟福胜,余丹绯,林志宇,等. 适形调强放疗联合或不联合化疗治疗≥5cm的非小细胞肺癌的临床疗效及不良反应[J]. 临床和实验医学杂志,2019, 18(13):1430-1432. DOI:10.3969/j.issn.1671-4695.2019.13.025.
Gou FS, Yu DF, Lin ZY, et al. Clinical efficacy and adverse reactions of conformal intensity modulated radiotherapy combined with or without chemotherapy in the treatment of non-small cell lung cancer ≥ 5cm[J]. J Clin Exp Med, 2019, 18(13):1430-1432. DOI:10.3969/j.issn.1671-4695.2019.13.025.